Introduction of solid-state cameras almost 10 years ago handed a needed lifeline to the stagnant technology. Increased imaging efficiency promised to accomplish both goals: shorter imaging times and lower radiation doses. Two systems equipped with Cadmium-Zinc-Telluride (CZT) detectors became commercially available: the Discovery 530 (GE Healthcare) and the D-SPECT (Spectrum Dynamics) cameras. 8, 9 Early adopters of the high-efficiency cameras experimented with optimal Tl-201 and Tc-99m doses, imaging times, and technicalities of image acquisition. The first papers appeared in 2009-2010 and explored image quality, diagnostic utility in a variety of patient populations, and compared images acquired on traditional Na-I cameras with the new technology. 10, 11 The ability to risk stratify and prognosticate future events is a cherished strength of SPECT imaging. 12 We now have data from 6 nuclear cardiology laboratories documenting the prognostic value of CZT SPECT imaging using lower radiation doses and shorter imaging times.
The latest contribution to the data is a paper from Sao Paolo, Brazil. 13 The authors followed two cohorts of SPECT MPI patients for 34 and 33 months, respectively, prior to and after the acquisition of CZT technology. Group 1 (N = 1,777 patients) underwent two-day (stress-rest) Tc-99m SPECT myocardial perfusion imaging (MPI) using a traditional Na-I camera during the years 2008-2010. Group 2 (N = 1,777 patients) underwent one-day (rest-stress) Tc-99m SPECT MPI using a CZT camera during the years 2011-2012. The patients were recruited from an initial pool of 6,128 patients, and propensity score matching was employed to make comparison possible. Group 1 (Na-I) had a slightly higher number of abnormal scans (27.4% vs 21.6%, p \ 0.001) compared to Group 2 (CZT) despite the demographic and risk factor matching used. The number of hard events in patients with a normal study was also higher in Group 1 (1.0% per year) compared to Group 2 (0.5% per year) (p \ 0.001). However, there was no difference in the number of hard events and revascularizations in patients with abnormal perfusion between the two groups during the follow-up (3.3% per year vs 3.2% per year, and 6.6% per year vs 6.3% per year, respectively). The current study therefore confirms the noninferiority for medium-term (33-34 months) prognosis of MPI results obtained from low-dose highefficiency SPECT studies compared to the results obtained from standard-dose Na-I SPECT imaging. This is despite the shorter acquisition time and low administered activity with the high-efficiency camera. The imaging time for the Na-I camera (two-day test) was 15 minutes, compared to 10 minutes using the CZT camera (one-day test), and the average Tc-99m dose was 25-40 mCi for the Na-I camera and 20 mCi for the CZT camera.
There are a number of weaknesses of the presented data. First, the non-simultaneous inclusion of the patients and temporal separation of the groups (before and after adoption of new technology) is not ideal, although this is somewhat offset by the use of propensity matching. Second, there is a disparity in the use of imaging protocols. A stress-rest two-day test was used for the traditional Na-I camera and a one-day rest-stress test employed for the CZT cohort. Therefore, the comparison between groups includes not only camera technology, image acquisition time, and administered activity, but also imaging sequence and timing. Neither of these first two factors allows for a meaningful explanation of the disparity in number of abnormal scans and less benign prognosis of a normal scan with the Na-I camera. Finally, the study lacks analysis and comparison of prognosis based on the perfusion defect size (mild, moderate, severe) which is a cornerstone of myocardial perfusion imaging.
Nevertheless, the authors' conclusions are consistent with previous studies utilizing high-efficiency SPECT cameras. Duvall et al followed 131 patients imaged with a high-efficiency camera with reduced acquisition times and of the traditional administered activity for one year.
14 Patients with normal perfusion had a benign prognosis with no cardiac deaths or nonfatal MI, and 2.3% of patients undergoing percutaneous coronary intervention. Nakazato et al followed 1,613 consecutive patients imaged using a solid-state camera for 2.6 years. 15 Prognosis was similar to results obtained using Na-I camera and was dependent on the perfusion defect size. The annual major adverse cardiac event (MACE) rate of a normal scan was 0.87%. Chowdhury et al followed 1,109 consecutive patients undergoing a two-day stress-rest study imaged with a CZT camera for 624 days (approximately 21 months). 16 The MACE rate was 0.4% for normal scans and 6.8% for abnormal scans. The results with the high-efficiency camera (imaging time 3-10 minutes, 15 mCi Tc-99m tetrofosmin for both stress and rest imaging) were consistent with imaging using a traditional SPECT camera. Oldan et al followed 2,088 patients for 2 years who underwent a two-day stress-rest SPECT during the same time period and were imaged using either a Na-I camera (N = 1,128 patients) or a CZT camera (N = 865 patients). 17 The number of hard events was similar using both technologies. Einstein et al followed 69 patients with a normal stress-only SPECT referred from the Emergency Department for the evaluation of acute chest pain. 18 Imaging was done on a CZT camera with Tc99m tetrofosmin with very low radiation exposure to the patient (0.99 mSv). There were no major adverse cardiac events at one year of follow-up. Yokota et al followed 1,650 consecutive (nonparallel) patients for 37 months with normal stress-first, CT attenuation corrected SPECT: 362 patients were imaged using a Na-I camera, and 1,288 patients were imaged using a CZT camera. 19 Stress-only imaging was used in 37% of patients imaged with the Na-I camera and in 61% of patients imaged with the CZT camera. The annual MACE rate was 2% and 1.5%, respectively (p = 0.08).
Even with different protocols, follow-up times and population cohorts, the message is similar: in more than 10,000 patients, the prognostic value of a normal and an abnormal stress SPECT study is similar if imaging is done using a traditional Na-I camera or a high-efficiency camera. However, imaging times are shorter and radiation doses are lower using the new technology.
What else has been learned in the past 7 years from the early adopters of solid-state cameras?
(1) Radiation doses can be markedly decreased for both Tc-99m and Tl-201. (2) Imaging times are decreased. Further lowering of radiation doses can be exchanged for longer imaging time. (3) Normal SPECT (rest-stress, stress-rest, or stressonly) and abnormal SPECT have similar risk stratification and prognostication value using both types of cameras. (4) Correlation with angiographic results is acceptable and comparable to imaging with Na-I cameras. (5) Obesity is a challenge despite of the optimistic conclusions of some papers. 20, 21 Most studies with CZT cameras excluded obese and morbidly obese patients. The literature suggests that perhaps D-SPECT camera (Spectrum Dynamics) is more suitable for imaging obese patients compared to the Discovery 530 (GE Healthcare). 22 What do we need to know in the future? Only preliminary data are available for some of the following: should include solid-state cameras for time to diagnosis, radiation dose, and cost effectiveness.
